Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection - PubMed (original) (raw)
Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection
Robert Zangerle et al. Clin Immunol. 2002 Sep.
Abstract
Antiretroviral therapy (ART) has a significant impact on HIV-1 RNA levels, the CD4 cell count, and immune activation. We examined whether these changes are associated with a change in the rate of tryptophan degradation (expressed as the kynurenine to tryptophan ratio, kyn/trp) as an estimate for the activity of interferon-gamma inducible enzyme indoleamine (, )-dioxygenase (IDO). Plasma levels of tryptophan, kynurenine, and neopterin were measured pretherapy and 6 months postinitiation of therapy in 45 patients with HIV-1 RNA levels of less than 1000 copies/ml 6 months after initiation of ART. Before ART, the patients had decreased tryptophan and increased kynurenine concentrations compared to healthy controls. During ART, average tryptophan levels increased; in the same time kynurenine and kyn/trp decreased (P < 0.001), although not to normal levels. Since pretherapy tryptophan concentrations correlated inversely with neopterin, and kynurenine correlated with viral load and neopterin but not with CD4 cell count, the data support the view that HIV production may induce immune activation and consequently tryptophan is degraded at a higher rate. In agreement, kyn/trp positively correlated with neopterin (r(s) = 0.60, P < 0.001), with virus load (r(s) = 0.37, P = 0.013), and very weakly with CD4(+) cells counts (r(s) = 0.30, P = 0.049). The change in the kyn/trp ratio during ART correlated more strongly with the change in neopterin levels (r(s) = 0.49, P = 0.001) than with the change in HIV RNA levels and weakly with the CD4 cell count. The data underscore the fact that both neopterin production and tryptophan degradation are triggered by immune activation. Tryptophan degradation is increased in HIV infection and partially reversed under ART. The data agree with the concept that immune activation is the common background of IDO activation which may be an important factor underlying T-cell hyporesponsiveness.
Similar articles
- Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection.
Neurauter G, Zangerle R, Widner B, Quirchmair G, Sarcletti M, Fuchs D. Neurauter G, et al. Adv Exp Med Biol. 2003;527:317-23. doi: 10.1007/978-1-4615-0135-0_35. Adv Exp Med Biol. 2003. PMID: 15206745 - Tryptophan degradation in patients with gynecological cancer correlates with immune activation.
Schroecksnadel K, Winkler C, Fuith LC, Fuchs D. Schroecksnadel K, et al. Cancer Lett. 2005 Jun 8;223(2):323-9. doi: 10.1016/j.canlet.2004.10.033. Epub 2004 Dec 8. Cancer Lett. 2005. PMID: 15896467 - Tryptophan degradation during and after gestation.
Schröcksnadel K, Widner B, Bergant A, Neurauter G, Schröcksnadel H, Fuchs D. Schröcksnadel K, et al. Adv Exp Med Biol. 2003;527:77-83. doi: 10.1007/978-1-4615-0135-0_8. Adv Exp Med Biol. 2003. PMID: 15206718 - Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.
Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Brown RR, et al. Adv Exp Med Biol. 1991;294:425-35. doi: 10.1007/978-1-4684-5952-4_39. Adv Exp Med Biol. 1991. PMID: 1722946 Review. - Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway.
Thomas SR, Stocker R. Thomas SR, et al. Redox Rep. 1999;4(5):199-220. doi: 10.1179/135100099101534927. Redox Rep. 1999. PMID: 10731095 Review.
Cited by
- Activation of the kynurenine pathway is associated with poor outcome in Pneumocystis pneumonia patients infected with HIV: results of 2 months cohort study.
Wang M, Dong X, Huang Y, Su J, Dai X, Guo Y, Hu C, Zhou Q, Zhu B. Wang M, et al. BMC Infect Dis. 2019 Mar 4;19(1):223. doi: 10.1186/s12879-019-3851-4. BMC Infect Dis. 2019. PMID: 30832615 Free PMC article. - Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis.
Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Gonzalez JS, et al. J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):181-7. doi: 10.1097/QAI.0b013e31822d490a. J Acquir Immune Defic Syndr. 2011. PMID: 21857529 Free PMC article. Review. - The kynurenine pathway activities in a sub-Saharan HIV/AIDS population.
Bipath P, Levay PF, Viljoen M. Bipath P, et al. BMC Infect Dis. 2015 Aug 19;15:346. doi: 10.1186/s12879-015-1087-5. BMC Infect Dis. 2015. PMID: 26285873 Free PMC article. - Stimulant Use, HIV, and Plasma Metabolites Among Men.
Cherenack EM, Larson ME, Murray K, Mayer ZJ, Guerrero C, Broedlow CA, Klatt NR, Carrico AW. Cherenack EM, et al. J Neuroimmune Pharmacol. 2025 Jun 19;20(1):68. doi: 10.1007/s11481-025-10223-4. J Neuroimmune Pharmacol. 2025. PMID: 40533682 - HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells.
Boasso A, Herbeuval JP, Hardy AW, Anderson SA, Dolan MJ, Fuchs D, Shearer GM. Boasso A, et al. Blood. 2007 Apr 15;109(8):3351-9. doi: 10.1182/blood-2006-07-034785. Epub 2006 Dec 7. Blood. 2007. PMID: 17158233 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials